<code id='FD878B49BD'></code><style id='FD878B49BD'></style>
    • <acronym id='FD878B49BD'></acronym>
      <center id='FD878B49BD'><center id='FD878B49BD'><tfoot id='FD878B49BD'></tfoot></center><abbr id='FD878B49BD'><dir id='FD878B49BD'><tfoot id='FD878B49BD'></tfoot><noframes id='FD878B49BD'>

    • <optgroup id='FD878B49BD'><strike id='FD878B49BD'><sup id='FD878B49BD'></sup></strike><code id='FD878B49BD'></code></optgroup>
        1. <b id='FD878B49BD'><label id='FD878B49BD'><select id='FD878B49BD'><dt id='FD878B49BD'><span id='FD878B49BD'></span></dt></select></label></b><u id='FD878B49BD'></u>
          <i id='FD878B49BD'><strike id='FD878B49BD'><tt id='FD878B49BD'><pre id='FD878B49BD'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:72981
          Eli Lilly headquarters
          Kristoffer Tripplaar/AP

          Eventually, the luckiest companies get to deal with a very particular problem: what to do when their stock could be getting ahead of itself.

          It’s a problem Eli Lilly got a little taste of Tuesday when it announced its full-year earnings. The drugmaker’s stock has more than doubled over the past 12 months due to the ever-increasing hopes for its GLP-1-based diabetes and weight loss drug, sold under the brand names Mounjaro and Zepbound. It was a big deal when Lilly became the first drug company ever to have a market value of $500 billion; it’s now sitting at a stunning $670 billion.

          advertisement

          At first, the earnings report suggested the company had blasted through expectations again, announcing fourth-quarter 2023 sales of $9.35 billion, almost half a billion dollars above analysts’ expectations, and also announcing new data for Mounjaro in treating metabolic dysfunction-associated steatohepatitis (MASH), a form of liver disease previously called NASH. Initially, shares traded up 5%.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Peter Hotez and the public health issue of online harassment
          Peter Hotez and the public health issue of online harassment

          AdobeFather’sDayweekendwasanythingbutcalmonTwitter,whicheruptedasvaccineexpertPeterHotezwaschallenge

          read more
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT
          Kristina Burow of ARCH Venture Partners shares her next big bets STAT

          AlexHogan/STATKristinaBurowhasawell-trainedeye.That’strueofherworkatARCHVenturePartners,oneofthedrug

          read more
          The cancer drug shortage isn’t new — and neither are the solutions
          The cancer drug shortage isn’t new — and neither are the solutions

          PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

          read more

          Obesity now affects over 1 billion people worldwide, study finds

          AdobeMorethan1billionpeople—oroneineightpeopleworldwide—arenowestimatedtohaveobesity,anewstudyfinds.